Literature DB >> 26636408

Nonalcoholic fatty liver is not associated with incident chronic kidney disease: a large histology-based comparison with healthy individuals.

Narendra S Choudhary1, Neeraj Saraf, Naveen Kumar, Rahul Rai, Sanjiv Saigal, Dheeraj Gautam, Lipika Lipi, Amit Rastogi, Sanjay Goja, Prashant Bhangui, Sumana K Ramchandra, Arvinder S Soin.   

Abstract

BACKGROUND: Nonalcoholic steatohepatitis or fibrosis is associated with the increased prevalence of impaired kidney function. It is not known whether nonalcoholic fatty liver (NAFL), which is steatosis without inflammation or fibrosis, is associated with renal impairment as these individuals are not candidates for liver biopsy.
MATERIALS AND METHODS: The study group included all liver donors who underwent a preoperative liver biopsy for various reasons. NAFL was defined as more than 5% hepatocytes having steatosis and no changes of steatohepatitis and/or fibrosis. Individuals with NAFL were compared with individuals with normal liver histology. Estimated glomerular filtration rate was calculated with the Modification of Diet in Renal Disease and Chronic Kidney Disease Epidemiology Collaboration methods.
RESULTS: The mean age of the study group was 35±10.3 years and the mean BMI was 26±3.2 kg/m. A total of 187 adults having NAFL (80 men) were compared with 186 (88 men) individuals with normal liver histology (controls). Individuals with steatosis had significantly higher BMI (26.8±3.5 vs. 25.5±3.8 kg/m, P<0.001) and serum alanine transaminase levels (33.8±13.3 vs. 27.2±9.8 IU/l, P<0.000). There was no significant difference in the estimated glomerular filtration rate between the normal histology group and the NAFL group with Modification of Diet in Renal Disease (115±21.8 vs. 114.4±23.2 ml/min, P=0.803) and Chronic Kidney Disease Epidemiology Collaboration methods (113.6±14.8 vs. 113±14.7 ml/min, P=0.668). There was no significant difference as regards serum creatinine (0.73±0.16 vs. 0.74±0.16 mg%, P=0.536), proteinuria (P=0.121), diabetes (1 vs. 4, P=0.372), and hypertension (2 vs. 6, P=0.174) in individuals of both groups.
CONCLUSION: Presence of NAFL does not adversely affect renal function.

Entities:  

Mesh:

Year:  2016        PMID: 26636408     DOI: 10.1097/MEG.0000000000000531

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

Review 1.  Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review.

Authors:  Raseen Tariq; Page Axley; Ashwani K Singal
Journal:  J Clin Exp Hepatol       Date:  2019-07-25

Review 2.  Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.

Authors:  Arka De; Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2019-09-20

Review 3.  Nonalcoholic fatty liver disease as a multi-systemic disease.

Authors:  Hakan Fotbolcu; Elçin Zorlu
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

4.  Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease.

Authors:  Ram V Nampoothiri; Ajay Duseja; Manish Rathi; Swastik Agrawal; Naresh Sachdeva; Manu Mehta; Harpal S Dhaliwal; Radha K Dhiman; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2017-12-30

Review 5.  Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver.

Authors:  Eda Kaya; Yusuf Yilmaz
Journal:  J Clin Transl Hepatol       Date:  2021-10-19

6.  Transaminase abnormalities and adaptations of the liver lobule manifest at specific cut-offs of steatosis.

Authors:  Andrew Hall; Claudia Covelli; Roberta Manuguerra; Tu Vinh Luong; Elena Buzzetti; Emmanuel Tsochatzis; Massimo Pinzani; Amar Paul Dhillon
Journal:  Sci Rep       Date:  2017-01-20       Impact factor: 4.379

Review 7.  Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease.

Authors:  Ziwen Tao; Yueyue Li; Baoquan Cheng; Tao Zhou; Yanjing Gao
Journal:  J Clin Transl Hepatol       Date:  2021-09-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.